DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016" drug pipelines to their offering.
This report provides comprehensive information on the therapeutic development for B1 Bradykinin Receptor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B1 Bradykinin Receptor and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
- Axxam SpA
- Boehringer Ingelheim GmbH
- Dompe Farmaceutici S.p.A.
- Grunenthal GmbH
Key Topics Covered:
- B1 Bradykinin Receptor Overview
- Therapeutics Development
- Pipeline Products for B1 Bradykinin Receptor - Overview
- Pipeline Products for B1 Bradykinin Receptor - Comparative Analysis
- B1 Bradykinin Receptor - Therapeutics under Development by Companies
- B1 Bradykinin Receptor - Therapeutics under Investigation by Universities/Institutes
- B1 Bradykinin Receptor - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- B1 Bradykinin Receptor - Products under Development by Companies
- B1 Bradykinin Receptor - Products under Investigation by Universities/Institutes
B1 Bradykinin Receptor - Companies Involved in Therapeutics Development
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/kwx3r3/b1_bradykinin